AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04076488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dividat Fit
Description: tablet based, remote assisted home-training
Study NCT01785121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured access to a Wii game computer (Wii)
Description: Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
Study NCT01785121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational support only
Description: The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
Study NCT00788229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT01
Description: eye drop for 12 weeks
Study NCT00788229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT02
Description: eye drop for 12 weeks
Study NCT00788229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT03
Description: eye drop for 12 weeks
Study NCT00788229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AT04
Description: eye drop for 12 weeks
Study NCT00588640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-Methadone
Description: 8 subjects to receive 40 mg d-Methadone twice a day
Study NCT00588640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-methadone
Description: After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
Study NCT00588640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
Study NCT01936519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A: Everolimus
Description: Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
Study NCT01936519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin Inhibitor
Description: Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
Study NCT02809612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based platform
Description: Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
Study NCT03773263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sequential IVM system
Description: The immature oocytes will be cultured in sequential oocyte IVM medium 1 for 6 hours (37℃, 5% CO2). After flushed 3 times, COCs were removed into sequential oocyte IVM medium 2 for further cultivation.
Study NCT03773263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracytoplasmic sperm injection (ICSI)
Description: intracytoplasmic sperm injection (ICSI)
Study NCT03773263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracytoplasmic sperm injection (ICSI)
Description: intracytoplasmic sperm injection (ICSI)
Study NCT03773263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thawed embryo transfer (TET)
Description: Patients administrates oestrogen (Progynova) 3mg twice a day for 10 to 12 days. From the day when endometrium reach a thickness of 8 mm and above, luteal phase support will be given with 10 mg progesterone (Dydrogesterone Tablets,) triple per day and utrogestan (Laboratories Besins International, Paris, France) 0.2g triple per day, until 14 days after embryo transfer.
Study NCT03773263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thawed embryo transfer (TET)
Description: Patients administrates oestrogen (Progynova) 3mg twice a day for 10 to 12 days. From the day when endometrium reach a thickness of 8 mm and above, luteal phase support will be given with 10 mg progesterone (Dydrogesterone Tablets,) triple per day and utrogestan (Laboratories Besins International, Paris, France) 0.2g triple per day, until 14 days after embryo transfer.
Study NCT03773263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: traditional IVM system
Description: COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed.
Study NCT04431453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as an intravenous infusion
Study NCT00609388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
Study NCT03574831 — intervention group
Intervention type: DEVICE
Intervention: Stretta
Description: Stretta
Study NCT00609388 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution 0.9% (250mL)
Description: intraoperative intraportal infusion of Saline solution 0.9% (250mL)
Study NCT00912093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Single subcutaneous injection of icatibant, 30 mg
Study NCT01636687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 injections of placebo to secukinumab 150mg per dose
Study NCT02728596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preventive Intervention
Description: Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN
Study NCT02728596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventive Intervention
Description: Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN
Study NCT02916095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanitinib
Description: Oral administration of Kanitinib tablets.
Study NCT02728596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02728596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00325650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00325650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study NCT04324918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1102
Description: The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
Study NCT04324918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP1408
Description: The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
Study NCT01636687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg
Description: Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
Study NCT01636687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300mg
Description: Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
Study NCT03924037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intergenerational Knowledge Sharing group
Description: Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the Intergenerational Knowledge Sharing group will attend 12 weekly groups taught by tribal elders that focuses on sharing knowledge about the tribe.
Study NCT03924037 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support group
Description: Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the support group will attend 12 weekly support groups led by a behavioral health specialist that focuses on social support of the youth.
Study NCT03888768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MonoFer
Description: Administration of IV Monofer will be given according to body weight as recommended by the drug manufacturer.
Study NCT06288334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-3 Cetirizine Pharmacokinetic samples
Description: Limited sampling strategy was used in this study. For each child, only 1\~3 blood samples were collected before and after cetirizine administration.
Study NCT01920490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GUILT-INCREASE-CORRELATION
Description: This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner
Study NCT01920490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GUILT-STABILIZE-CORRELATION
Description: This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner
Study NCT02728596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02728596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04470141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHC014748M treatment
Description: Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
Study NCT03425916 — intervention group
Intervention type: OTHER
Intervention: Physical therapy intervention
Description: Primiparous women start a physical therapy intervention in week 6 after normal one-child delivery, based on abdominal and pelvic floor exercises, education and behavior advices. Abdominal muscle condition and activation are measured by transabdominal ultrasound and surface electromiography. This group is going to be examined after treatment and 6 and 12 months after treatment.
Study NCT04036019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD20-directed CAR-T cells with CliniMACS Prodigy® system
Description: Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
Study NCT02167789 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Paradym CRT 8770
Study NCT03138603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate
Description: Patients will be randomly assigned to receive up-to-three intravenous doses of 5mg metoprolol tartrate (over 15-minutes) at the end of their surgical procedure, and a scheduled oral dose regimen of 25mg metoprolol approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
Study NCT03064932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled feeding diet
Description: Average American diet with different levels of spices
Study NCT03064932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled feeding diet
Description: Average American diet with different levels of spices
Study NCT03522064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate 100 MG/ML Injectable Solution
Description: Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
Study NCT03522064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
Description: Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
Study NCT03138603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
Study NCT02488525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with Wilfactin
Description: Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
Study NCT04257084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: chromoendoscopy with target biopsy; NBI with target biopsy
Description: Chromoendoscopy with target biopsy: 0.03% indigo carmine solution based chromoendoscopy (using high-definition colonoscopy) will be fulfilled and target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia.~NBI with target biopsy: After inserting a high definition colonoscopy up to cecum, endoscopists observe the colon in combination of white light and NBI (white light first and then NBI). Target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia.
Study NCT04591119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Thoracic Muscle Plane Block
Description: 40 ml %0.375 bupivacaine divided into 4 equal doses will be injected by the surgeon between internal intercostal muscle and transversus thoracis muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space
Study NCT04591119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parasternal Intercostal Plane Block
Description: 40 ml %0.375 bupivacaine injection will be performed by ultrasound guidance after completion of surgery between pectoralis major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally by anesthesiologist.
Study NCT04398576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training and support
Description: GP's receive the tools to make early identification of harmful and hazardous alcohol use possible. They are given guidelines to apply a brief intervention. At the start of the study, the T\&S-group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months.
Study NCT04398576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community actions
Description: There will be embedded community-based actions within a local strategy.
Study NCT01343888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 48 weeks
Study NCT00912093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single subcutaneous injection of matching placebo
Study NCT02556372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JKB-122
Description: Orally administered capsules of JKB-122 which will be taken once daily with dose escalation from 5mg up to 40mg depending on the monthly response.
Study NCT01343888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN/RBV
Description: PegIFN/RBV for 48 weeks
Study NCT01343888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 once daily high dose
Study NCT04341077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3162
Description: A single oral dose of fluzoparib on Day 1
Study NCT02714374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GL-ONC1
Description: Dose and Regimen:~1. Single dose group: Cohort 1 dose is 1 × 109 pfu~2. Multiple dose groups:~   * Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~  * Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~  * Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection.
Study NCT01264757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Educational Materials
Description: A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
Study NCT01264757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
Study NCT03325127 — intervention group
Intervention type: DRUG
Intervention: radium Ra 223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injections
Study NCT01343888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: BI 201335 once daily low dose
Study NCT01343888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03325127 — intervention group
Intervention type: DRUG
Intervention: Zytiga
Description: Abiraterone 1000 mg per day orally
Study NCT03325127 — intervention group
Intervention type: DRUG
Intervention: Xtandi
Description: Enzalutamide 160 mg per day orally
Study NCT00603174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurally adjusted ventilatory assist (NAVA)
Description: Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
Study NCT05412303 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: age, gender, body weight, height, personal medical history, ASA score, EuroSCORE2, type of cardiac surgery, the preoperative left ventricular ejection fraction, the duration of CPB, the duration of aortic clamping, the need for intraoperative blood transfusion, norepinephrine, dobutamine, creatinine value, time to extubation (hours), any occurrence of complications during the stay in the ICU or in the hospital, and the LOS in the ICU and hospital
Study NCT00030147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: 60 mg a day orally administered
Study NCT00030147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimostil
Description: 1000 mg twice a day administered orally
Study NCT00030147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Estradiol
Description: 100 microgram per day transdermal estradiol
Study NCT00030147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo skin patch and placebo tablets
Description: matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
Study NCT00785694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hexaminolevulinate
Description: Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
Study NCT03482544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pragabalin
Description: pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.
Study NCT03482544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.
Study NCT01471808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII
Description: continuous subcutaneous insulin infusion for 2\~4 weeks
Study NCT01471808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII, Metformin, Pioglitazone
Description: CSII for 2\~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
Study NCT02860754 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Six-minute walk test to perform before surgery
Description: During the outpatient preoperative assessment, eligible patients will perform the six-minute walk test.
Study NCT02210104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
Study NCT02210104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2 administered intravenously 2 days prior to T cell infusion.
Study NCT02210104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4+ T cells
Description: Antigen-specific CD4+ T cells administered at a dose of 10\^10 cells/m\^2 on Day 0.
Study NCT02541006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg
Description: tiotropium 18 mcg once a day
Study NCT02541006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg
Description: tiotropium 18 mcg once a day
Study NCT01480492 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Telbivudine
Description: 600mg,1/d,one year
Study NCT01471808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII, Sitagliptin
Description: CSII for 2\~4 weeks combined with sitagliptin 100mg/d for 3 months